Blood Thinners Lawsuit: Pradaxa, Xarelto, and Andexxa Claims

The blood thinner lawsuits of the 2010s targeted three newer anticoagulants — Xarelto, Pradaxa, and Eliquis — and alleged that their manufacturers marketed them as safer than warfarin while hiding that no antidote existed to stop a life-threatening bleed. Two of those fights ended in settlements totaling more than $1.4 billion. The third was dismissed. A new round of litigation is now forming around Andexxa, the only approved reversal agent for Xarelto and Eliquis, which was pulled from the U.S. market in December 2025.

What the Lawsuits Alleged

Xarelto (rivaroxaban), Pradaxa (dabigatran), and Eliquis (apixaban) were approved by the FDA between 2010 and 2012 to prevent strokes and blood clots. They were sold as more convenient than warfarin, which requires regular blood monitoring and dietary restrictions. They shared one serious problem: warfarin can be reversed with vitamin K, and none of the newer drugs had an approved antidote when they reached patients.

The core allegations across the three drug lines were nearly identical. Plaintiffs claimed the manufacturers knew the drugs carried a heightened bleeding risk with no reliable way to reverse it, and marketed them anyway as low-maintenance alternatives.¹ The specific legal theories included:

Failure to warn patients and prescribing physicians about the full severity of bleeding risks and the absence of an antidote. One Xarelto lawsuit alleged the label omitted information about a blood test that could have helped emergency physicians determine how much of the drug was in a patient’s system.²
Design defect, on the theory that a blood thinner with no emergency reversal mechanism was unreasonably dangerous.²
Misrepresentation, with Eliquis plaintiffs alleging the manufacturers concealed knowledge of defects and misrepresented safety and efficacy data.³

The injuries claimed were fatal and life-threatening internal hemorrhaging, gastrointestinal bleeding, hemorrhagic stroke, and wrongful death. Plaintiffs sought compensation for medical expenses, lost wages, pain and suffering, and loss of consortium.⁴

Pradaxa: $650 Million Settlement

Pradaxa, made by Boehringer Ingelheim, was the first of the newer anticoagulants to face mass litigation. By 2014, roughly 4,000 lawsuits had been filed over bleeding events, including fatal hemorrhages.⁵

In May 2014, Boehringer Ingelheim agreed to pay $650 million to resolve the claims. The company’s general counsel said Boehringer Ingelheim “believed from the outset that the plaintiffs’ claims lacked merit” but entered the settlement to avoid the “distraction” of prolonged litigation.⁵ Individual payouts were approximately $150,000 per plaintiff, covering medical bills, lost wages, and pain and suffering.⁴

Pradaxa’s litigation also diverged from the others for a clinical reason. In October 2015, the FDA granted accelerated approval to Praxbind (idarucizumab), a Boehringer Ingelheim reversal agent for Pradaxa, with full approval following in April 2018.⁶ The existence of that antidote largely took away the “no reversal agent” argument that kept driving cases against the other two drugs.

Xarelto: $775 Million Settlement

Xarelto generated the largest volume of lawsuits. Federal cases were consolidated in December 2014 into Multidistrict Litigation No. 2592 before Judge Eldon E. Fallon in the Eastern District of Louisiana.⁷ A separate mass tort program ran in Philadelphia.⁸ The defendants were Janssen Pharmaceuticals (a Johnson & Johnson subsidiary) and Bayer.

The manufacturers won every bellwether trial. The first three federal trials ended in defense verdicts, including a June 2017 trial in which the jury sided with Bayer and Janssen after about two hours of deliberation despite the plaintiff having died from a brain bleed.⁹¹⁰¹¹

Even with that trial record, more than 25,000 cases were still pending. On March 25, 2019, Bayer and Johnson & Johnson announced a $775 million settlement to resolve virtually all outstanding U.S. claims, split equally at $387.5 million each. Neither company admitted liability.¹²¹³

The average payout was about $31,000, with amounts varying by injury severity. Claimants who filed after December 1, 2015, or whose injuries first occurred after March 1, 2016, received substantially reduced payouts.¹⁴⁸ More than 99% of plaintiffs opted into the settlement, which the defendants fully funded by January 2020.¹⁵

Why Eliquis Lawsuits Were Dismissed

Eliquis cases ended differently. The Judicial Panel on Multidistrict Litigation consolidated them in February 2017 as MDL No. 2754 in the Southern District of New York before Judge Denise Cote.³ The defendants, Bristol-Myers Squibb and Pfizer, built their defense on federal preemption: because the FDA had approved the Eliquis label, state-level failure-to-warn claims could not override it.

Under FDA regulations, a manufacturer can unilaterally update a label through the “changes being effected” process, but only to reflect newly acquired information about risks of a different type, greater severity, or higher frequency than what the FDA already knew. Without that new information, the manufacturer cannot change the label, and a state court cannot punish it for not changing it.¹⁶

In May 2017, Judge Cote dismissed the lead case, Utts v. Bristol-Myers Squibb, finding the bleeding risks of Eliquis were “known and public” at approval and the label adequate. Other dismissals followed, and by mid-2017 only one case remained in the MDL.¹⁷ In March 2019, the Second Circuit affirmed the dismissal of 64 products liability claims in Gibbons v. Bristol-Myers Squibb Co., finding the plaintiffs’ allegations “conclusory and vague.”¹⁶ No bellwether trials were held, no settlement was reached, and as of 2026, no attorneys are known to be accepting new Eliquis bleeding lawsuits.³

The Andexxa Recall and the New Wave of Claims

In 2018, the FDA granted accelerated approval to Andexxa (andexanet alfa), the first and only approved reversal agent for patients on Xarelto or Eliquis experiencing life-threatening bleeding.¹⁸¹⁹

On December 18, 2025, the FDA announced that Andexxa’s risks outweighed its benefits. AstraZeneca, which had acquired the drug’s manufacturer, voluntarily withdrew the product and ceased U.S. commercial sales on December 22, 2025.¹⁸ Leslie Lake of the National Blood Clot Alliance said the withdrawal happened “quickly with little communication,” and that many patients were never notified.¹⁹

Attorneys are now evaluating claims on behalf of patients who received Andexxa and then suffered strokes, heart attacks, pulmonary embolisms, deep vein thrombosis, or death, alleging that AstraZeneca failed to adequately research and warn about these risks.²⁰ As of mid-2026, no formal MDL consolidation or major filings have been publicly announced.

The withdrawal also matters for people still taking Xarelto or Eliquis. With no approved reversal agent available, physicians are relying on off-label use of Kcentra, a clotting factor concentrate not FDA-approved for this purpose and carrying its own clot risks.²⁰

Can You Still File a Blood Thinner Lawsuit?

It depends on which drug and which injury.

The Pradaxa and Xarelto settlements are closed. The Xarelto MDL was fully funded by January 2020, with common benefit fees distributed to participating attorneys.¹⁵ Eliquis bleeding claims face the preemption bar set by Gibbons, which requires any new plaintiff to identify specific newly acquired risk information that postdated FDA approval and that the manufacturers failed to act on.¹⁶ As of 2026, attorneys are not generally accepting new Eliquis bleeding cases.³

The active area is Andexxa. Patients who received Andexxa and then suffered a stroke, heart attack, blood clot, or related injury — or the families of patients who died — are the group attorneys are currently evaluating.²⁰

One structural point matters for anyone considering a claim: these cases were not class actions. They were individual lawsuits consolidated into multidistrict litigation for shared discovery and pretrial rulings, with each plaintiff proving their own injuries and damages. That is why Pradaxa payouts averaged about $150,000 and Xarelto payouts about $31,000 — the amount depended on the specific case.⁴

Statutes of limitations for drug injury claims vary by state but generally run two to three years from when the plaintiff knew or should have known that their injury was linked to the drug. Because that deadline turns on when the connection was discovered, timing in Andexxa cases will be fact-specific, and anyone considering a claim should get the deadline confirmed for their state before waiting.

1
AboutLawsuits.com. Xarelto Lawsuit
2
Enjuris. Xarelto Lawsuits
3
Drugwatch. Eliquis Lawsuits
4
ClassAction.org. Apixaban Bleeding Risk Lawsuit
5
Medscape. Pradaxa Litigation Settlement
6
Drugs.com. Praxbind FDA Approval History
7
U.S. District Court, Eastern District of Louisiana. Xarelto MDL
8
ConsumerSafety.org. Xarelto Lawsuit Information
9
Wilkinson Stekloff. Wilkinson Walsh Secures Second Decisive Victory for Bayer in Xarelto Trial
10
Drugwatch. $28M Xarelto Verdict Overturned
11
Fierce Pharma. Plaintiff’s Xarelto Victory Short-Lived as Judge Overturns $28M Verdict
12
Bayer. Bayer Reaches Settlement to Resolve Xarelto Litigation
13
CNBC. Bayer, J&J Settle Blood Thinner Xarelto Litigation for $775 Million
14
NBC News. Xarelto Suits: Bayer, Janssen Agree to $775 Million Settlement
15
U.S. District Court, Eastern District of Louisiana. In Re: Xarelto Products Liability Litigation, MDL No. 2592
16
FindLaw. Gibbons v. Bristol-Myers Squibb Co.
17
Fierce Pharma. BMS, Pfizer Come Up Victorious in 20 More Eliquis Cases
18
U.S. Food and Drug Administration. Update on Safety of Andexxa
19
Medscape. Anticoagulant Reversal Drug Andexxa Voluntarily Pulled From U.S. Market
20
AboutLawsuits.com. Andexxa Lawsuit